- Home
- PLX vs RDCM Comparison
PLX vs RDCM Comparison
Compare PLX & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- RDCM
- Stock Information
- Founded
- PLX 1993
- RDCM 1985
- Country
- PLX United States
- RDCM Israel
- Employees
- PLX N/A
- RDCM N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- RDCM Computer peripheral equipment
- Sector
- PLX Health Care
- RDCM Technology
- Exchange
- PLX Nasdaq
- RDCM Nasdaq
- Market Cap
- PLX 160.2M
- RDCM 210.3M
- IPO Year
- PLX 1998
- RDCM 1997
- Fundamental
- Price
- PLX $1.55
- RDCM $13.41
- Analyst Decision
- PLX Strong Buy
- RDCM Strong Buy
- Analyst Count
- PLX 1
- RDCM 2
- Target Price
- PLX $15.00
- RDCM $16.00
- AVG Volume (30 Days)
- PLX 1.4M
- RDCM 62.5K
- Earning Date
- PLX 05-09-2025
- RDCM 05-14-2025
- Dividend Yield
- PLX N/A
- RDCM N/A
- EPS Growth
- PLX N/A
- RDCM 111.69
- EPS
- PLX 0.05
- RDCM 0.53
- Revenue
- PLX $59,764,000.00
- RDCM $63,477,000.00
- Revenue This Year
- PLX $65.02
- RDCM $16.58
- Revenue Next Year
- PLX $57.34
- RDCM $11.48
- P/E Ratio
- PLX $32.18
- RDCM $25.35
- Revenue Growth
- PLX 0.18
- RDCM 18.21
- 52 Week Low
- PLX $0.82
- RDCM $9.05
- 52 Week High
- PLX $3.10
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- PLX 30.03
- RDCM 61.29
- Support Level
- PLX $1.54
- RDCM $12.65
- Resistance Level
- PLX $1.79
- RDCM $13.55
- Average True Range (ATR)
- PLX 0.11
- RDCM 0.67
- MACD
- PLX -0.02
- RDCM 0.01
- Stochastic Oscillator
- PLX 27.27
- RDCM 51.15
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.